A novel endogenous mediator of cutaneous inflammation: leukemia inhibitory factor.
DOI:
https://doi.org/10.2340/0001555576111114Abstract
Keratinocytes produce a variety of cytokines, including leukemia inhibitory factor. We hypothesised that this cytokine may play a pro-inflammatory role in the skin and tested this hypothesis by injecting recombinant leukemia inhibitory factor (1-100 ng) into the ear pinnae of C3H/HeJ mice. To other groups of animals, we injected boiled leukemia inhibitory factor or phosphate-buffered saline (negative control) or 0.4 ng human interleukin-1 alpha as a positive control. Following injection of 100 ng leukemia inhibitory factor, ear thickness, measured by micrometer, increased 66% over controls at 12 h and 100% at 24 h (overall p = 0.041 by analysis of variance). Injection of 0.4 ng interleukin-1 alpha caused greater ear swelling. Compared with controls, swelling increased by 67% at 6 h, 100% at 12 h and 340% after 24 h (overall p < or = 0.00001). Leukemia inhibitory factor (100 ng only) stimulated a 3.5-fold increase in leukocytes after 6 h. After 12 h, a 14-fold increase was seen in ears injected with 10 ng leukemia inhibitory factor and a 12-fold increase with 100 ng leukemia inhibitory factor, which remained elevated (17-fold) at 24 h (overall p = 0.0001). Injection of interleukin-1 alpha led to a 3.4-fold increase in leukocytes (mean per 20 high-power fields) after 6 h, a 14-fold increase at 12 h and a 25-fold increase at 24 h (overall p < or = 0.00001). These results demonstrate that leukemia inhibitory factor appears to be a mediator of cutaneous inflammation.Downloads
Downloads
Published
How to Cite
Issue
Section
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.